secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001701541-23-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Q1 net loss $20.9M; cash $103.4M; BDTX-1535 update H2 2023; BDTX-4933 IND cleared
--------------------------------------------------------------------------------

- Cash $103.4M as of March 31, down from $122.8M at year-end 2022; net loss $20.9M vs $25.5M in Q1 2022.
- Cash runway expected into Q3 2024.
- Phase 1 dose escalation of BDTX-1535 ongoing; clinical update on track for H2 2023; dose-expansion cohorts to open in 2023.
- FDA clearance for BDTX-4933 IND; first patient dosing expected in Q2 2023.
- Development candidate BDTX-4876 (FGFR 2/3 selective) nominated; company evaluating strategic alternatives for FGFR program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/0001701541-23-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/bdtx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001701541-23-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer